Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
Both authors contributed equally.
- 10.2991/chi.d.191128.001How to use a DOI?
- Acute myeloid leukemia; Timed sequential chemotherapy; EMA; Chemotherapy; Refractory AML; Relapsed AML; AML
Therapy for those with relapsed or refractory acute myeloid leukemia is suboptimal. Studies have suggested that timed sequential salvage combination cytotoxic chemotherapy may be particularly useful for that indication. We report here a series of ten such adult patients treated sequentially at a single center with EMA (cytarabine 500 mg/m2/day as continuous infusion on days 1–3 and days 8–10, mitoxantrone 12 mg/m2/day on days 1–3, and etoposide 200 mg/m2/day as continuous infusion on days 8–10). The overall complete remission rate was 40% (including 3 of 4 of those with relapsed disease), but use of this regimen was associated with prolonged cytopenia and a high rate of infectious adverse events. Even with the availability of modern infectious prophylaxis and therapies, the EMA regimen is likely best reserved for those with relapsed disease treated with curative intent prior to an allogeneic hematopoietic cell transplant.
- © 2019 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.
- Open Access
- This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
Download article (PDF)
View full text (HTML)
Cite this article
TY - JOUR AU - Bogdan Popescu AU - Sheenu Sheela AU - Julie Thompson AU - Sophia Grasmeder AU - Therese Intrater AU - Christin B. DeStefano AU - Christopher S. Hourigan AU - Catherine Lai PY - 2019 DA - 2019/12/09 TI - Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia JO - Clinical Hematology International SP - 27 EP - 31 VL - 2 IS - 1 SN - 2590-0048 UR - https://doi.org/10.2991/chi.d.191128.001 DO - 10.2991/chi.d.191128.001 ID - Popescu2019 ER -